Central Nervous System Targeted Protein Degraders

Diseases of the central nervous system, which once occupied a large component pharmaceutical industry research and development portfolio, have for many years played smaller part in major pharma pipelines—primarily due to well cited challenges target validation, valid translational models, clinical trial design. Unfortunately, this decline interest has occurred tandem with an increase medical need—in driven by success treating other chronic diseases, then results greater overall longevity along higher prevalence diseases associated ageing. The lead modality drug agents targeting brain remains traditionally small molecule, despite potential gene-based therapies antibodies, particularly hugely anticipated anti-amyloid field, clearly additional challenge effective distribution relevant compartments. However, recognition growing disease burden, advanced are being developed improved delivery options. Hence, methodologies were initially restricted systemic indications now actively explored range CNS diseases—an important class include protein degradation technologies.